|Feb 16, 2018|
|Feb 16, 2018|
Currency in INR
|Full time employees:||22,671|
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates from hit generation to pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Dr. Reddy's Laboratories is a leading Indian generic drugmaker that operates business in more than 20 countries. Founder K. Anji Reddy is among the business leaders who spearheaded the development of India's generic drug industry.
The company was founded in 1984, and its generic drug business found its way to a growth track in 1986. It continues to steadily expand in 2000s. It has made acquisitions and now has development bases in the U.K. and the Netherlands.
Dr. Reddy's Laboratories has been stepping up its biomedicine operations. These include the development of anti-cancer drugs, which the company considers a big source of future earnings. Dr. Reddy's Laboratories aims to reinforce its biomedicine operations through a tie-up with the German drugmaker Merck.
Anji Reddy died in 2013. His son, Satish Reddy, serves as company chairman and his son-in-law as co-chairman. The founding family owns nearly 25% of the company's shares.
In the news
India's biggest drug maker says U.S. pricing environment `challenging'
February 14, 2018 9:56 pm JST
Philippine's Bloomberry Resorts, Indian pharmaceuticals shine in troubled market
February 9, 2018 10:16 pm JST
Global equity selloff, India move to tax share-sale profit hurt appetite
February 9, 2018 9:11 pm JST
Software exporters, drug makers among major gainers
February 8, 2018 9:13 pm JST
India's third-biggest drug maker says U.S. business starting to stabilize
February 6, 2018 9:12 pm JST
India's Sensex and Shanghai Composite hit hardest, both down 2.7% on week
February 3, 2018 5:28 am JST
- Local currency
- US Dollar
|Income before tax||14,304M|
|Dividends per share||20|
|Operating cash flow||21,216M|
Currency in INR
|Income before tax||213.31M|
|Dividends per share||0.29|
|Operating cash flow||316.38M|
Currency in USD
- Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
- President, CFO & Global Head-IT: Saumen Chakraborty
- Chief Operating Officer: Abhijit Mukherjee
- Secretary & Compliance Officer: Sandeep Poddar
- EVP, Head-Emerging Markets & Global Generics: M. V. Ramana
- Dr. Reddy's Holdings Ltd.(24.7%)
- First State Investment Management (UK) Ltd.(6.2%)
- OppenheimerFunds, Inc.(3.8%)
- Life Insurance Corp. of India(3.5%)
- Reliance Nippon Life Asset Management Ltd. (Invt Mgmt)(2.3%)
- BlackRock Fund Advisors(2.1%)
- Franklin Advisers, Inc.(1.9%)
- Franklin Templeton Asset Management (India) Pvt Ltd.(1.7%)
- Aditya Birla Sun Life AMC Ltd.(1.5%)
- TELUK KEMANG INVESTMENTS MAURITIUS LTD(1.2%)
- Website: http://www.drreddys.com
- Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
- Phone: +91.40.49002900
Copyright © 2018 FactSet Research Systems Inc. All rights reserved.